Crews Bank & Trust Purchases New Shares in argenx SE (NASDAQ:ARGX)

Crews Bank & Trust bought a new position in argenx SE (NASDAQ:ARGX) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 935 shares of the company’s stock, valued at approximately $575,000.

Several other institutional investors and hedge funds have also bought and sold shares of ARGX. Blue Trust Inc. grew its holdings in argenx by 46.2% in the fourth quarter. Blue Trust Inc. now owns 541 shares of the company’s stock worth $333,000 after purchasing an additional 171 shares during the period. SG Americas Securities LLC grew its stake in shares of argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after acquiring an additional 21 shares during the last quarter. Atomi Financial Group Inc. purchased a new position in shares of argenx in the fourth quarter worth $339,000. Crossmark Global Holdings Inc. boosted its position in shares of argenx by 2.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 9,714 shares of the company’s stock worth $5,974,000 after acquiring an additional 252 shares during the last quarter. Finally, Ballentine Partners LLC increased its holdings in argenx by 21.5% in the 4th quarter. Ballentine Partners LLC now owns 536 shares of the company’s stock valued at $330,000 after acquiring an additional 95 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $717.00 price target (up previously from $670.00) on shares of argenx in a report on Tuesday, January 14th. Baird R W downgraded argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. lifted their target price on argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. JMP Securities boosted their target price on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $675.00 price target (up previously from $646.00) on shares of argenx in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and an average price target of $658.39.

argenx Price Performance

argenx stock opened at $660.31 on Thursday. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21. The stock has a market capitalization of $39.86 billion, a PE ratio of -749.72 and a beta of 0.59. The business has a 50 day simple moving average of $630.29 and a 200-day simple moving average of $567.59.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period last year, the firm posted ($1.25) earnings per share. On average, equities research analysts anticipate that argenx SE will post 2.78 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.